Artificial virus capsid

By modifying the β-annulus peptide with a fluorine-containing compound, the artificial virus capsids achieve improved cell membrane permeability, enabling efficient cellular delivery of substances, addressing the limitations of existing capsids in this regard.

WO2024228371A1PCT designated stage expired Publication Date: 2024-11-07AGC INC +2
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016503
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-04-26
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Existing artificial virus capsids lack effective cell membrane permeability, limiting their ability to efficiently deliver substances into cells.

Method used

Modification of the β-annulus peptide with a fluorine-containing compound, specifically a fluorine-containing peptide, to enhance cell membrane permeability by self-assembling into artificial virus capsids with a divalent linking group connected to the C-terminus, allowing for improved cellular uptake.

Benefits of technology

The modified artificial virus capsids exhibit enhanced cell membrane permeability, facilitating efficient delivery of substances into cells, making them suitable for pharmaceutical applications as drug delivery carriers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016503_07112024_PF_FP_ABST
    Figure JP2024016503_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides an artificial virus capsid modified with a compound containing a fluorine atom. The present invention relates to an artificial virus capsid formed by self-assembly of a plurality of subunits, wherein the subunits each contain a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound and a divalent linking group that links the β-annulus peptide and the group derived from the fluorine-containing compound, and the divalent linking group is linked to the C-terminus of the β-annulus peptide.
Need to check novelty before this filing date? Find Prior Art

Description

Artificial viral capsids

[0001] The present invention relates to an artificial virus capsid modified with a compound containing a fluorine atom. This application claims priority to Japanese Patent Application No. 2023-076053, filed on May 2, 2023, the contents of which are incorporated herein by reference.

[0002] Spherical artificial viral capsids can be created by in vitro self-assembly of β-annulus peptides derived from proteins that form the dodecahedral internal skeleton of the capsid of Tomato Bushy Stunt Virus (Non-Patent Documents 1-4). The β-annulus peptide is a 24-amino acid long peptide, the smallest unit, corresponding to a portion of the 388-amino acid capsid protein. The β-annulus peptide spontaneously self-assembles in water to form spherical, hollow nanocapsules, or artificial viral capsids, with a diameter of approximately 30-50 nm. In these nanocapsules, the N-terminus of the β-annulus peptide faces the interior of the hollow capsule and the C-terminus faces the exterior of the hollow capsule. It has been demonstrated that various substances can be encapsulated in these artificial viral capsids (either in the form of free molecules or in a form that binds to or interacts with the N-terminus of the β-annulus peptide). These encapsulated substances are also called guests, and depending on the type of guest, the diameter of the artificial viral capsid may be somewhat enlarged. It has also been demonstrated that by linking molecules such as gold nanoparticles, 20-nucleotide single-stranded DNA, coiled-coil-forming peptides, human serum albumin, and ribonuclease S near the C-terminus of a β-annulus peptide, artificial viral capsids can be formed whose outer surface is modified with these molecules. It has also been reported that modified artificial viral capsids obtained by linking a nucleic acid aptamer having a length of 40 nucleotides or more to the C-terminus of a β-annulus peptide and then allowing it to self-assemble can be efficiently and specifically delivered (e.g., introduced into specific target cells) via the aptamer moiety (Patent Document 1).

[0003] On the other hand, compounds having a polyfluoro structure are known to be stable and low in toxicity in vivo, and to be excellent in uptake into cells and escape from endosomes. Utilizing these properties, studies have been conducted to introduce a polyfluoro structure into oligonucleotides or peptide nucleic acids as a moiety capable of penetrating cell membranes (Patent Documents 2 and 3).

[0004] Polyfluoro structures have also been introduced into peptides. For example, it has been reported that fluorine-containing peptides having fluorine-containing amino acids with polyfluoroalkyl groups introduced into their side chains have good cell membrane permeability (Patent Document 4).

[0005] JP 2022-173834 A International Publication No. 2012 / 130941 International Publication No. 2021 / 060506 International Publication No. 2023 / 048236

[0006] Chem. Commun., 2018, vol.54, p.8944.Bioconjugate Chem. 2019, vol.30, p.1636-1641.J. Org. Chem. 2020, vol.85, p.1668-1673.J Pept Sci. 2017, vol.23(7-8), p.636-643.Kostrzewa-Nowak et al., British Journal of Cancer, 2005, vol.93, p.89-97.

[0007] An object of the present invention is to provide an artificial virus capsid that has excellent cell membrane permeability.

[0008] The present inventors discovered that by modifying the β-annulus peptide of Tomato Bushy Stunt Virus (TBSV) with a peptide containing an amino acid residue having a fluorine atom introduced into the side chain, the cell membrane permeability of the artificial viral capsid obtained by self-assembly of the β-annulus peptide can be improved, and thus completed the present invention.

[0009] That is, the present invention is as follows. [1] An artificial virus capsid formed by self-assembly of a plurality of subunits, wherein the subunits contain a β-annular peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound, and a bivalent linking group linking the β-annular peptide to the group derived from the fluorine-containing compound, and the bivalent linking group is linked to the C-terminus of the β-annular peptide. [2] The artificial virus capsid of [1] above, wherein the fluorine-containing compound is a fluorine-containing peptide. [3] At least one side chain of an amino acid residue constituting the fluorine-containing peptide has a structure represented by the following general formula (1):

[0010]

[0011] [In the formula, Z 1 is a di-, tri-, or tetravalent linking group other than an alkylene group; Rf is a C 1-30 Alkyl group (the C 1-30 When the alkyl group has two or more carbon atoms, it may have 1 to 5 ether-bonding oxygen atoms between the carbon atoms), -SF 5 , or -SF 4 -CR 101 R 102 -CR 103 R 104 Cl(R 101 , R 102 , R 103 , and R 104 are each independently a hydrogen atom, a fluorine atom, or a chlorine atom, but R 101 , R 102 , R 103 , and R 104 wherein two or more of the Rf are fluorine atoms; n3 is 1, 2, or 3; n4 is 0 or 1; and a black circle represents a bond. [4] The artificial virus capsid according to [2] above, wherein the Rf is a group represented by the following general formula (f-1) or (f-2):

[0012]

[0013] [wherein, Rf Pis a fully halogenated C containing at least two fluorine atoms. 1-10 Alkyl group (the fully halogenated C 1-10 [5] The artificial virus capsid of [3] above, wherein the amino acid residue having the group represented by general formula (1) as a side chain is an amino acid residue having 1 to 3 Rf's linked directly or indirectly to the side chain of a natural amino acid. [6] The artificial virus capsid of any of [1] to [5] above, wherein the divalent linking group is a bis-maleimide group containing maleimide groups at both ends. [7] The artificial virus capsid of any of [1] to [6] above, wherein the β-annulus peptide has a cysteine ​​residue at or near the C-terminus, and the divalent linking group is linked to a thiol group derived from the cysteine ​​residue. [8] A pharmaceutical composition comprising the artificial virus capsid of any one of [1] to [7]. [9] A drug delivery carrier composition comprising the artificial virus capsid of any one of [1] to [7].

[0014] The artificial viral capsid according to the present invention is modified with a group derived from a fluorine-containing compound, and therefore has excellent cell membrane permeability. Therefore, the artificial viral capsid is expected to be used in the pharmaceutical field as a carrier for physiologically active substances or drug delivery (DDS carrier).

[0015] 1(A) shows a reversed-phase HPLC chart and MALDI-TOF-MS results (FIG. 1(B)) in the purification of β-Annulus-Cys peptide in Example 1. FIG. 2(A) shows a reversed-phase HPLC chart and MALDI-TOF-MS results (FIG. 2(B)) in the purification of TMR-β-Annulus-Cys peptide in Example 1. FIG. 3(A) shows a reversed-phase HPLC chart and MALDI-TOF-MS results (FIG. 3(B)) in the purification of β-Annulus-PEG2-maleimide in Example 1. FIG. 4(A) shows a reversed-phase HPLC chart and MALDI-TOF-MS results (FIG. 4(B)) in the purification of TMR-β-Annulus-PEG2-maleimide in Example 1. FIG. 4(B) shows a reversed-phase HPLC chart and MALDI-TOF-MS results (FIG. 4(B)) in the purification of TMR-β-Annulus-CAD in Example 1. C8F17 5A shows a reversed-phase HPLC chart and FIG. 5B shows the results of MALDI-TOF-MS in the purification of F peptide. C8F17 6A and 6B show the reversed-phase HPLC chart and the MALDI-TOF-MS results, respectively, of the purification of F peptide. C8F17 7(A) shows a reversed-phase HPLC chart and MALDI-TOF-MS results for the purification of F peptide (FIG. 7(B)). FIG. 8(A) shows the results of measuring the particle size distribution (number function distribution) of fluorine-containing peptide-modified capsids in Example 1. FIG. 8(A) shows the results of measuring the particle size distribution (number function distribution) of β-Annulus-CAD C8F17 8(B) shows the results for fluorine-containing peptide-modified capsids formed in a solution containing 50 μM of F peptide, and FIG. 8(C) shows the results for β-Annulus-CAD. C8F171 shows the results for fluorine-containing peptide-modified capsids formed in a solution with an F peptide concentration of 10 μM. This is a TEM image of a fluorine-containing peptide-modified capsid in Example 1. This is a diagram showing the results of measuring the particle size distribution (number function distribution) of TMR-labeled fluorine-containing peptide-modified capsids in Example 1. This is a TMR fluorescence image, a merged image of the TMR fluorescence image and Hoechst 33342 fluorescence image, and a transmitted light image of cells into which a TMR-labeled fluorine-containing peptide-modified capsid was introduced (top row), cells into which a TMR-labeled fluorine-containing peptide was introduced (middle row), and cells into which a TMR-labeled capsid was introduced (bottom row) in Example 1. This is a diagram showing the results of measuring the TMR fluorescence intensity of cells into which a TMR-labeled fluorine-containing peptide-modified capsid was introduced (left column), cells into which a TMR-labeled fluorine-containing peptide was introduced (center column), and cells into which a TMR-labeled capsid was introduced (right column) in Example 1. 14(A) and 14(B) show the results of flow cytometry analysis of untreated cells (A), cells into which a TMR-labeled, fluorine-containing peptide-modified capsid was introduced (B), cells into which a TMR-labeled, fluorine-containing peptide was introduced (C), and cells into which a TMR-labeled capsid was introduced (D) in Example 1 (left: dot plot, right: histogram). 14(A) shows the results of measurement of the percentage (%) of cells that have taken up TMR in untreated cells, cells into which a TMR-labeled, fluorine-containing peptide-modified capsid was introduced, cells into which a TMR-labeled, fluorine-containing peptide was introduced, and cells into which a TMR-labeled capsid was introduced (D) in Example 1 (FIG. 14(A)). 14(B) shows the results of measurement of the median TMR fluorescence intensity in untreated cells, cells into which a TMR-labeled, fluorine-containing peptide-modified capsid was introduced, and cells into which a TMR-labeled capsid was introduced (FIG. 14(B)). 14(B) shows the results of measurement of the particle size distribution (number function distribution) of Dox-encapsulated fluorine-containing peptide-modified capsids in Example 2 (FIG. 14(A)). 14(B) shows the results of measurement of the particle size distribution (number function distribution) of Dox-encapsulated fluorine-containing peptide-modified capsids in Example 2 (FIG. 14(B ... 1 shows the results of measuring the UV-vis spectra and Dox binding rate (%) of capsids modified with a fluoropeptide encapsulated in Dox and capsids unmodified with a fluoropeptide encapsulated in Dox in Example 2. FIG. 2 shows the results of measuring the cell viability (%) of cells transfected with capsids modified with a fluoropeptide encapsulated in Dox in Example 2.FIG. 1 shows TMR fluorescence images of cells cultured in a medium containing only TMR-labeled fluorine-containing peptide-modified capsid (Control), cells cultured in a medium containing TMR-labeled fluorine-containing peptide and EIPA (80 μM EIPA), cells cultured in a medium containing TMR-labeled fluorine-containing peptide and Pitstop2 (20 μM Pitstop2), and cells cultured in a medium containing TMR-labeled capsid and Genistein (160 μM Genistein) in Example 3. This figure shows the results of measuring the TMR fluorescence intensity of cells cultured in a medium containing only TMR-labeled fluorine-containing peptide-modified capsid (Control), cells cultured in a medium containing TMR-labeled fluorine-containing peptide and EIPA (EIPA), cells cultured in a medium containing TMR-labeled fluorine-containing peptide and Pitstop2 (Pitstop2), and cells cultured in a medium containing TMR-labeled capsid and Genistein (Genistein) in Example 3. In Example 4, β-Annulus-CAD. C6F13 21(A) shows a reversed-phase HPLC chart and ESI-MS results for the purification of F peptide (FIG. 21(B)). In Example 4, cells into which mCherry mRNA was introduced using a transfection reagent (left panel), CAD C6F13 1 shows Hoechst 33342 fluorescence images, mCherry fluorescence images, merged images of mCherry and Hoechst 33342 fluorescence images, and transmitted light images of cells into which mCherry mRNA was introduced using an F peptide-modified artificial viral capsid (middle column) and cells into which mCherry mRNA was introduced using an unmodified artificial viral capsid (right column). In Example 4, cells into which mCherry mRNA was introduced using a transfection reagent (left column), CAD C6F13 FIG. 10 shows the mCherry fluorescence intensity of cells into which mCherry mRNA was introduced using an F peptide-modified artificial viral capsid (center column) and cells into which mCherry mRNA was introduced using an unmodified artificial viral capsid (right column).

[0016] In the present invention and the present specification, "C p1-p2" (p1 and p2 are positive integers satisfying p1<p2) means that the group has at least p1 and at most p2 carbon atoms.

[0017] In the present invention and the present specification, "C 1-30 The "alkyl group" is an alkyl group having 1 to 30 carbon atoms, and may be a straight chain or a branched chain. 2-30 The "alkyl group" is an alkyl group having 2 to 30 carbon atoms, and may be a straight chain or a branched chain. 1-30 Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, a dodecyl group, a tridecyl group, a tetradecyl group, a pentadecyl group, a hexadecyl group, a heptadecyl group, an octadecyl group, a nonadecyl group, an eicosyl group, a heneicosyl group, a docosyl group, a tricosyl group, a tetracosyl group, a pentacosyl group, a hexacosyl group, a heptacosyl group, an octacosyl group, a nonacosyl group, and a triacontyl group.

[0018] In the present invention and the present specification, "C 1-10 The "alkyl group" is an alkyl group having 1 to 10 carbon atoms, and may be a straight chain or a branched chain. 2-10 The "alkyl group" is an alkyl group having 2 to 10 carbon atoms, and may be a straight chain or a branched chain. 1-10 Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, and a decyl group.

[0019] In the present invention and the present specification, "C 1-6 The "alkyl group" is an alkyl group having 1 to 6 carbon atoms, and may be a straight chain or a branched chain. 1-6Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, and a hexyl group.

[0020] In the present invention and the present specification, "C 6-14 The term "aryl group" refers to an aromatic hydrocarbon group having 6 to 14 carbon atoms, 6-12 An aryl group is particularly preferred. 6-14 Examples of the aryl group include a phenyl group, a naphthyl group, an anthryl group, and a 9-fluorenyl group, with a phenyl group being particularly preferred.

[0021] In the present invention and the present specification, "optionally substituted C 6-14 The "aryl group" is C 6-14 It is a group in which one or more, preferably 1 to 3, hydrogen atoms bonded to a carbon atom of an aryl group are substituted with other functional groups. When two or more substituents are present, the substituents may be the same or different from each other. Examples of the substituents include a nitro group, a halogen atom (a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom), a C 1-6 Alkyl group, C 1-6 Alkoxy groups and methylenedioxy groups (—O—CH 2 -O-) and the like. 6-14 Examples of the "aryl group" include a phenyl group, a naphthyl group, an anthryl group, a 4-nitrophenyl group, a 4-methoxyphenyl group, a 2,4-dimethoxyphenyl group, a 3,4-dimethoxyphenyl group, a 4-methylphenyl group, a 2,6-dimethylphenyl group, a 3-chlorophenyl group, and a 1,3-benzodioxol-5-yl group.

[0022] In the present invention and the present specification, "C 6-14 Aryl-C 1-6 The alkyl group is C 1-6 One hydrogen atom bonded to a carbon atom of the alkyl group is C 6-14 It is a group substituted with an aryl group. 6-14 Aryl-C 1-6 C in alkyl group 6-14Examples of the aryl group include a phenyl group, a naphthyl group, an anthryl group, and a 9-fluorenyl group, with a phenyl group or a 9-fluorenyl group being particularly preferred. 6-14 Aryl-C 1-6 C in alkyl group 1-6 The alkyl group may be C 1-4 Alkyl groups are preferred. 6-14 Aryl-C 1-6 Examples of the alkyl group include a benzyl group, a diphenylmethyl group, a triphenylmethyl group, a 2-phenylethyl group, a 9-anthrylmethyl group, and a 9-fluorenylmethyl group.

[0023] In the present invention and this specification, the term "halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. The term "halogen atom other than a fluorine atom" refers to a chlorine atom, a bromine atom, or an iodine atom. Preferred examples of "halogen atoms other than a fluorine atom" include a chlorine atom or a bromine atom, with a chlorine atom being particularly preferred.

[0024] In the present invention and the present specification, "C 1-6 The "alkoxy group" refers to a C 1-6 A group in which an oxygen atom is bonded to the bonding terminal of an alkyl group. 1-6 The alkoxy group may be a straight chain or a branched chain. 1-6 Examples of the alkoxy group include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a tert-butoxy group, a pentyloxy group, and a hexyloxy group.

[0025] In the present invention and this specification, an "ether-bonded oxygen atom" refers to an oxygen atom that links carbon atoms, and does not include oxygen atoms in which oxygen atoms are linked in series. An alkyl group having Nc carbon atoms (Nc is an integer of 2 or more) may have a maximum of Nc-1 ether-bonded oxygen atoms.

[0026] In the following description, "compound n" means a compound represented by formula (n).

[0027] The artificial virus capsid according to the present invention is an artificial virus capsid formed by the self-assembly of a plurality of subunits, each of which contains a β-annular peptide of TBSV, a group derived from a fluorine-containing compound, and a bivalent linking group that links the β-annular peptide to the group derived from the fluorine-containing compound. In the artificial virus capsid, the bivalent linking group is linked to the C-terminus of the β-annular peptide, and therefore the group derived from the fluorine-containing compound is displayed on the outside of the hollow capsule of the artificial virus capsid.

[0028] <β-annulus peptide> The β-annulus peptide of TBSV (hereinafter simply referred to as "β-annulus peptide") is publicly known and is reviewed in Non-Patent Document 1. The β-annulus peptide consists of the amino acid sequence represented by INHVGGTGGAIMAPVAVTRQLVGS (SEQ ID NO: 1). Of the amino acid sequence of SEQ ID NO: 1, the regions 1 to 5, the regions 10 to 13, and the regions 17 to 22 are essential portions for forming an artificial viral capsid by self-assembly (hereinafter sometimes referred to as "β-annulus peptide consensus sequence"), and are the minimum unit capable of forming an artificial viral capsid by self-assembly in water.

[0029] The β-annulus peptide used in the present invention and the present specification is not particularly limited, as long as it contains a β-annulus peptide consensus sequence and can form an artificial viral capsid by self-assembly in water. For example, it may be a peptide consisting only of the amino acid sequence represented by SEQ ID NO: 1. The region of the amino acid sequence represented by SEQ ID NO: 1 other than the consensus sequence of the β-annulus peptide may be substituted with other amino acid residues, deleted, or have other amino acid residues or amino acid sequences added, as long as it does not inhibit the formation of the artificial viral capsid. Furthermore, an additional amino acid sequence may be added to the C-terminus and / or N-terminus of SEQ ID NO: 1.

[0030] Previous studies have demonstrated that an artificial viral capsid can be formed even when an additional amino acid sequence is added to the C-terminus and / or N-terminus of SEQ ID NO: 1. In the present invention and this specification, the β-annulus peptide may be a peptide consisting of an amino acid sequence in which, for example, 1 to 20 amino acid residues, 1 to 10 amino acid residues, or 1 to 5 amino acid residues have been added to the N-terminus and / or C-terminus of the amino acid sequence represented by SEQ ID NO: 1.

[0031] The amino acid sequence added to the amino acid sequence represented by SEQ ID NO: 1 is not particularly limited as long as it does not inhibit the formation of an artificial viral capsid by self-assembly, and may be, for example, a linker sequence for linking the β-annulus peptide to another substance that modifies the β-annulus peptide. It is within the skill of those skilled in the art to synthesize a peptide so that a functional group useful for linker binding or the linker itself is present at the N-terminus and / or C-terminus of the amino acid sequence represented by SEQ ID NO: 1.

[0032] In the present invention and this specification, a "subunit" refers to a unit molecule that forms an artificial viral capsid through self-assembly. Each subunit contains at least a β-annulus peptide. However, the multiple subunits that self-assemble into a single artificial viral capsid are not necessarily identical to one another; for example, embodiments in which subunits modified with a fluorine-containing compound and subunits without a fluorine-containing compound are mixed are also contemplated. Artificial viral capsids formed by the self-assembly of multiple subunits, each of which is modified with a different fluorine-containing compound, are also contemplated. As described in Non-Patent Documents 1 to 4, self-assembly refers to the spontaneous combination of multiple β-annulus peptide-containing subunits in water or an aqueous solution to form a roughly spherical artificial viral capsid, and the structure thus formed. The diameter of each artificial viral capsid formed by self-assembly (measured by DLS (dynamic light scattering)) can vary depending on the presence and type of guest, but is typically 30 to 100 nm. One artificial viral capsid is estimated to contain approximately 60 subunits. The pH of the aqueous solution during self-assembly is typically 5 to 9, and can be, for example, 6 to 8, or 6.5 to 7.5. The concentration of the subunits during self-assembly can be, for example, 1 to 50 μM, 3 to 40 μM, or 5 to 30 μM.

[0033] The β-annulus peptides used in the present invention and the present specification preferably have a cysteine ​​residue at or near the C-terminus, specifically, 1 to 5 amino acid residues from the C-terminus, and more preferably 2 to 5 amino acid residues from the C-terminus. Note that "1 amino acid residue from the C-terminus" refers to the amino acid residue at the C-terminus. Examples of β-annulus peptides having a cysteine ​​residue at or near the C-terminus include a peptide consisting of an amino acid sequence (SEQ ID NO: 2) in which the second amino acid residue (G) from the C-terminus of SEQ ID NO: 1 is substituted with a cysteine ​​residue, a peptide (SEQ ID NO: 3) in which the C-terminal amino acid residue (S) of SEQ ID NO: 1 is substituted with a cysteine ​​residue, and a peptide consisting of an amino acid sequence obtained by adding a peptide consisting of 1 to 4 amino acids to the C-terminus of these amino acid sequences. Furthermore, the peptide may also be an amino acid sequence obtained by adding an amino acid sequence consisting of 1 to 5 amino acids containing a cysteine ​​residue to the C-terminus of the amino acid sequence of SEQ ID NO: 1. The amino acid sequence having a cysteine ​​residue to be added to the C-terminus of the amino acid sequence of SEQ ID NO: 1 is preferably an amino acid sequence of 1 to 5 amino acids in which all residues other than the cysteine ​​residue are glycine residues, since this minimizes the effect on artificial viral capsid formation, and more preferably an amino acid sequence of 2 to 5 amino acids in which the second residue from the C-terminus is a cysteine ​​residue and the remaining residues are all glycine residues.

[0034] The β-annulus peptide used in the present invention and the present specification may have a cysteine ​​residue at or near the N-terminus, specifically one to five amino acid residues from the N-terminus, and preferably one amino acid residue from the N-terminus. Having a cysteine ​​residue at or near the N-terminus facilitates modification of the N-terminus of the β-annulus peptide with other substances. An example of a β-annulus peptide having a cysteine ​​residue at or near the N-terminus is a peptide consisting of an amino acid sequence in which an amino acid sequence consisting of one to five amino acids containing a cysteine ​​residue is added to the N-terminus of the amino acid sequence of SEQ ID NO: 1. The amino acid sequence having a cysteine ​​residue added to the N-terminus of the amino acid sequence of SEQ ID NO: 1 is preferably an amino acid sequence of one to five amino acids in which all residues except the cysteine ​​residue are glycine residues, since this minimizes the effect on artificial viral capsid formation. An amino acid sequence of two to five amino acids in which the first residue from the N-terminus is a cysteine ​​residue and the remaining residues are all glycine residues is more preferred.

[0035] <Group derived from a fluorine-containing compound> As used in the present invention and this specification, the term "group derived from a fluorine-containing compound" refers to a group in which one hydrogen atom has been removed from a fluorine-containing compound having at least one fluorine atom to form a bond. In order to more fully obtain the effect of improving cell membrane permeability due to fluorine, the "group derived from a fluorine-containing compound" used in the present invention is preferably a group having a group represented by the following general formula (1). In general formula (1), a black circle represents a bond.

[0036]

[0037] In the general formula (1), Rf represents a C group substituted with at least two fluorine atoms. 1-30 Alkyl group, -SF 5 , or -SF 4 -CR 101 R 102 -CR 103 R 104 It is Cl.

[0038] Rf is C substituted with at least two fluorine atoms 1-30When it is an alkyl group, the C 1-30 The alkyl group has two or more carbon atoms (C 2-30 In the case of an alkyl group, the alkyl group may have 1 to 5 ether-bonding oxygen atoms between carbon atoms.

[0039] In Rf, one or more hydrogen atoms bonded to the carbon atom may be further substituted with a halogen atom other than a fluorine atom. 1-30 The alkyl group may be C 1-20 Alkyl groups are preferred, and C 1-10 Alkyl groups are more preferred, and C 2-10 Alkyl groups are more preferred, and C 2-8 An alkyl group is even more preferred. 2-30 When Rf is an alkyl group, it may have 1 to 5 ether-bonded oxygen atoms between carbon atoms. The number of hydrogen atoms substituted with fluorine atoms in Rf is not particularly limited as long as it is 2 or more, and is, for example, preferably 3 or more, more preferably 6 or more, and even more preferably 7 or more.

[0040] Examples of Rf include a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, a perfluorohexyl group, a perfluoroheptyl group, a perfluorooctyl group, a perfluorononyl group, a perfluorodecyl group, a difluoromethyl group, a 1,1-difluoroethyl group, a 2,2-difluoroethyl group, a 1,1,2,2-tetrafluoroethyl group, Examples thereof include a 1,1,2,2,3,3-hexafluoropropyl group, a 1,1,2,3,3,3-hexafluoropropyl group, a 1,1,2,2,3,3-hexafluorohexyl group, a 1,1,2,2,3,3-hexafluorooctyl group, a 1,1,2,2,3,3-hexafluorodecyl group, a 1,1,2,2,3,3-hexafluorooctadecyl group, and a 1,1,2,2,3,3-hexafluorohexacosyl group.

[0041] When Rf is a group having 2 carbon atoms, Rf is preferably a 1,1,1-trifluoroethyl group (CF 3 -CH 2A group in which at least four hydrogen atoms bonded to a carbon atom are substituted with fluorine atoms, such as a pentafluoroethyl group, is preferred over a group having three carbon atoms, such as a 1,1,1,3,3,3-hexafluoropropan-2-yl group ((CF 3 ) 2 -CH-) and (CF 3 ) 2 A —CF— group is preferred. When Rf is a group having 4 carbon atoms, Rf may be a linear group or a branched group. In the case of a branched group, it is preferred that the hydrogen atoms bonded to the carbon atoms constituting the alkylene group moiety are substituted with fluorine atoms, or that the group is completely fluorinated.

[0042] Rf is preferably a group represented by the following general formula (f-1) or (f-2): In general formulas (f-1) and (f-2), a black circle represents a bond.

[0043]

[0044] In general formulas (f-1) and (f-2), Rf P is a fully halogenated C containing at least two fluorine atoms. 1-10 represents an alkyl group. P is C 1-10 Rf is a group in which all of the hydrogen atoms of the alkyl group are substituted with halogen atoms, and at least two of the halogen atoms are fluorine atoms. P When the carbon number is 2 or more, that is, when the completely halogenated C 2-10 In the case of an alkyl group, it may have 1 to 5 ether-bonding oxygen atoms between carbon atoms. P may be the same group or different groups.

[0045] In the following general formula (f-1) or (f-2), n1 is an integer of 0 to 10, and n2 is an integer of 0 to 9. When n1 and n2 are 0, they both represent a single bond. That is, when n1 is 0, the group represented by general formula (f-1) is Rf P-, and when n2 is 0, the group represented by general formula (f-2) is (Rf P ) 2 It is —CH—.

[0046] When Rf is a group represented by general formula (f-1), Rf is Rf P is preferably a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, a perfluorohexyl group, a perfluoroheptyl group, a perfluorooctyl group, a perfluorononyl group, or a perfluorodecyl group, and n1 is an integer of 0 to 4; P is more preferably a group in which n1 is an integer of 0 to 2, and Rf P is a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, or a perfluorohexyl group, and n1 is an integer of 0 to 2 (wherein n1 is 1 and Rf P is a trifluoromethyl group) is more preferred.

[0047] When Rf is a group represented by general formula (f-2), Rf is Rf P is preferably a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, a perfluorohexyl group, a perfluoroheptyl group, a perfluorooctyl group, a perfluorononyl group, or a perfluorodecyl group, and n2 is an integer of 0 to 4; P is more preferably a group in which n2 is an integer of 0 to 2, and Rf is a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, a perfluorohexyl group, a perfluoroheptyl group, a perfluorooctyl group, a perfluorononyl group, or a perfluorodecyl group, and n2 is an integer of 0 to 2; Pis a trifluoromethyl group, a pentafluoroethyl group, a heptafluoropropyl group, a nonafluorobutyl group, a perfluoropentyl group, or a perfluorohexyl group, and n2 is an integer of 0 to 2 (wherein n2 is 0 or 1 and Rf P is a trifluoromethyl group) is more preferred.

[0048] Examples of Rf include a difluoromethyl group, a 1,1-difluoroethyl group, a 2,2-difluoroethyl group, a 1,1,2,2-tetrafluoroethyl group, a 1,1,2,2,3,3-hexafluoropropyl group, and a 1,1,2,3,3,3-hexafluoropropyl group.

[0049] Rf is -SF 4 -CR 101 R 102 -CR 103 R 104 When the group is represented by Cl, R 101 , R 102 , R 103 , and R 104 are each independently a hydrogen atom, a fluorine atom, or a chlorine atom. 101 , R 102 , R 103 , and R 104 At least two of the —SF groups are fluorine atoms. 4 -CR 101 R 102 -CR 103 R 104 Specific examples of the group represented by Cl include -SF 4 -CF 2 -CF 2 Cl, -SF 4 -CF 2 -CFCl 2 , -SF 4 -CF 2 -CHF-Cl, -SF 4 -CF 2 -CCl 3 , -SF 4 -CF 2 -CHCl 2 , -SF 4 -CF 2 -CH 2 Cl, -SF4 -CFCl-CFCl 2 , -SF 4 -CFCl-CHF-Cl, -SF 4 -CHF-CHF-Cl.

[0050] In general formula (1), Z 1 is a di-, tri-, or tetravalent linking group other than an alkylene group, n3 is 1, 2, or 3, and n4 is 0 or 1. When n4 is 0, -(Z 1 ) n4- represents a single bond. Z 1 is not particularly limited as long as it is a divalent to tetravalent group other than an alkylene group. For example, Z 1 represents an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, a trivalent nitrogen atom, -C(=O)-, -S(=O) 2 Examples of the aryl and heteroaryl groups include alkylene groups, groups in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, groups in which 2 to 4 hydrogen atoms have been removed from an aromatic ring (aryl group), groups in which 2 to 4 hydrogen atoms have been removed from a heterocycle (heteroaryl group), and combinations thereof. The aryl and heteroaryl groups may be any of the groups listed above. However, these groups exclude groups consisting solely of alkylene groups and groups in which the linking moiety to Rf is an alkylene group.

[0051] Z 1 is an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, -C(=O)-, -S(=O) 2 -, a group in which two hydrogen atoms have been removed from a cycloalkane, a group in which two hydrogen atoms have been removed from an aromatic ring, a group in which two hydrogen atoms have been removed from a heterocycle, or a combination thereof, Z 1 is a divalent linking group, and the group represented by general formula (1) is a group having one Rf group. 1When has a trivalent nitrogen atom, two Rf groups can be bonded to the nitrogen atom directly or via another divalent linking group, thereby making the group represented by general formula (1) a group having two Rf groups.

[0052] Z 1 Z may be a linking group having a group (cyclic group) in which a hydrogen atom has been removed from a ring, or may be a linking group not having a cyclic group. 1 When Z has a cyclic group, the group represented by general formula (1) can be a group having two or three Rf groups. Examples of the cyclic group include groups in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, an aromatic ring, or a heterocyclic ring. As the heterocyclic ring, a ring in which 1 to 3 carbon atoms of the aromatic ring are substituted with one or more atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom is preferred. In addition, the cyclic group may be a group in which a hydrogen atom has been removed from a single ring, or a group in which a hydrogen atom has been removed from a fused ring. Z in general formula (1) 1 The ring group contained in is preferably a group in which 2 to 4 hydrogen atoms have been removed from cyclohexane, benzene, imidazole, or indole. For example, Z 1 is a linking group having a ring group formed by removing 2 to 4 hydrogen atoms from benzene, the ring group is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group, and a 1,4-phenylene group or a 1,3,5-substituted phenyl group is preferred.

[0053] Specifically, Z in general formula (1) 1 -C(=O)-, -C(=O)-O-, -OC(=O)-, -NH-C(=O)-O-, -OC(=O)-NH-, -C(=O)-NH-, -NH-C(=O)-, -S-S-, -S(=O) 2 -NH-, -NH-S (=O) 2 -, -S(=O) 2 —NH—S(═O) 2 -, -C(=O)-NH-Ph- (-Ph- is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group). 1-6It is also preferable that the linking group is a combination of alkylene groups. 1 As the group, the linking moiety to Rf is preferably an oxygen atom.

[0054] Z in general formula (1) 1 is preferably a linking group represented by the following general formula (2): In general formula (2), the black circle represents a bond.

[0055]

[0056] In general formula (2), Z 2 is a di-, tri-, or tetravalent linking group other than an alkylene group. 2 is not particularly limited as long as it is a divalent to tetravalent group other than an alkylene group. For example, Z 2 represents an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, a trivalent nitrogen atom, -C(=O)-, -S(=O) 2 Examples of the aryl and heteroaryl groups include alkylene groups, groups in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, groups in which 2 to 4 hydrogen atoms have been removed from an aromatic ring (aryl group), groups in which 2 to 4 hydrogen atoms have been removed from a heterocycle (heteroaryl group), and combinations thereof. The aryl and heteroaryl groups may be any of the groups listed above. However, these groups exclude groups consisting solely of alkylene groups and groups in which the linking moiety to Rf is an alkylene group.

[0057] Z in general formula (2) 2 Specifically, Z 1 The same as those listed in the general formula (2) can be used. 2 -C(=O)-, -C(=O)-O-, -OC(=O)-, -NH-C(=O)-O-, -OC(=O)-NH-, -C(=O)-NH-, -NH-C(=O)-, -S-S-, -S(=O) 2 -NH-, -NH-S (=O) 2 -, -S(=O) 2 —NH—S(═O)2 Preferably, it is -, -C(=O)-NH-Ph- (-Ph- is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group).

[0058] In the general formula (2), Rh is a hydrogen atom or C 1-6 Rh is an alkyl group. 1-6 In the case of an alkyl group, Rh is C 1-3 An alkyl group is preferred, and a methyl group or an ethyl group is more preferred.

[0059] Examples of the group represented by formula (1) include Z 1 is a group represented by general formula (2), and Rf is a group represented by general formula (f-1) or (f-2). 2 is -C(=O)-, -C(=O)-O-, -OC(=O)-, -NH-C(=O)-O-, -OC(=O)-NH-, -C(=O)-NH-, -NH-C(=O)-, -S-S-, -S(=O) 2 -NH-, -NH-S (=O) 2 -, -S(=O) 2 —NH—S(═O) 2 -, -C(=O)-NH-Ph- (-Ph- is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group), and Rh is a hydrogen atom or C 1-6 It is preferably an alkyl group in which Rf is a group represented by general formula (f-1) or (f-2).

[0060] The group derived from a fluorine-containing compound in the subunit of the artificial viral capsid according to the present invention is not particularly limited, as long as it is a group having at least one fluorine atom and does not inhibit the formation of an artificial viral capsid by self-assembly of the β-annulus peptide when linked to the β-annulus peptide. Examples of fluorine-containing compounds having such a group include groups derived from peptides, nucleic acids, low molecular weight compounds, and compounds in which a fluorine atom or a fluorine-containing group has been introduced into a chimeric molecule consisting of two or more of these. Compounds in which at least one hydrogen atom in a peptide, nucleic acid, or low molecular weight compound has been substituted with a group represented by the general formula (1) are preferred.

[0061] The group derived from a fluorine-containing compound possessed by the artificial virus capsid according to the present invention is preferably a fluorine-containing amino acid residue or a fluorine-containing peptide. The fluorine-containing amino acid is preferably an amino acid having a group represented by the general formula (1) bonded to its α-carbon. The fluorine-containing peptide is preferably a peptide in which at least one side chain of an amino acid residue constituting the peptide is a group represented by the general formula (1) or a group containing the group.

[0062] The fluorine-containing peptide contained in the artificial virus capsid according to the present invention is a peptide having a side chain containing a group represented by the general formula (1) [-(Z 1 )n4-(Rf)n3], or a peptide having one or more amino acid residues in which 1 to 3 Rf groups are linked directly or indirectly to the side chain of a natural amino acid. Specific examples of the fluorine-containing peptide contained in the artificial virus capsid according to the present invention include peptides in which one or two hydrogen atoms of the amino group in the side chain of an arginine residue, asparagine residue, glutamine residue, or lysine residue are substituted with -Rf or -Z. 3 -(Rf)n5(Z 3 is a di-, tri-, or tetravalent linking group other than an alkylene group, provided that groups in which the linking moiety to Rf is an alkylene group are excluded. Also, n5 is 2, 3, or 4.) 3an amino acid residue substituted with -(Rf)n5; an amino acid residue substituted with -Rf or -Z in which the hydrogen atom of the carboxyl group in the side chain of an aspartic acid residue or a glutamic acid residue is substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; a cysteine ​​residue or a methionine residue, wherein the hydrogen atom of the thiol group in the side chain is substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; a hydrogen atom of a hydroxy group in the side chain of a serine residue, a threonine residue, or a tryptophan residue substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the benzene ring in the side chain of a tyrosine residue or a phenylalanine residue are substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the imidazole ring in the side chain of a histidine residue substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the indole ring in the side chain of a tryptophan residue are substituted with -Rf or -Z 3 -A peptide having at least one amino acid residue substituted with (Rf)n5 is preferred.

[0063] Z 3 is not particularly limited as long as it is a divalent to tetravalent group other than an alkylene group. For example, Z 3 represents an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, a trivalent nitrogen atom, -C(=O)-, -S(=O) 2 -, a group in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, a group in which 2 to 4 hydrogen atoms have been removed from an aromatic ring (aryl group), a group in which 2 to 4 hydrogen atoms have been removed from a heterocycle (heteroaryl group), or a combination thereof. As the aryl group and heteroaryl group, the groups listed above can be used. However, this does not include a group consisting of only an alkylene group or a group in which the linking moiety to Rf is an alkylene group. Specifically, Z 3 As for Z, 1 and Z 2 The same linking groups as those shown in the above can be used.

[0064] -Rf or -Z of a hydrogen atom of an amino group, imino group, carboxy group, hydroxy group, thiol group, benzene ring, imidazole ring, indole ring, etc. in the side chain of a natural amino acid 3 The substitution to -(Rf)n5 can be carried out by a general synthetic reaction such as an ester reaction.

[0065] The fluorine-containing peptide contained in the artificial virus capsid of the present invention is a peptide having -(Z 1 Among the amino acid residues constituting the peptide, at least one side chain of which has -(Z)n4-(Rf)n3 is preferred. 1 )n4-(Rf)n3, and the side chains of all amino acid residues are -(Z 1 )n4-(Rf)n3. 1 When there are two or more amino acid residues having -(Z)n4-(Rf)n3, these two or more -(Z 1 )n4-(Rf)n3 may be the same or different from each other. 1 The amino acid residue having (Rf)n4-(Rf)n3 may be at the N-terminus, the C-terminus, or at a position other than the terminal.

[0066] The fluorine-containing peptide contained in the artificial virus capsid according to the present invention may be a peptide consisting of two or more amino acids, and a peptide consisting of three or more amino acids is also preferred. The number of amino acid residues constituting the fluorine-containing peptide contained in the artificial virus capsid according to the present invention is preferably 2 to 20, more preferably 3 to 20, even more preferably 3 to 10, and even more preferably 3 to 6.

[0067] Among the fluorine-containing peptides contained in the artificial virus capsid of the present invention, the side chain is -(Z 1The amino acid residue that is not -(Rf)n4-(Rf)n3 is not particularly limited, and may be an α-amino acid residue, a β-amino acid residue, a γ-amino acid residue, or a δ-amino acid residue. Furthermore, it may be an L-amino acid residue or a D-amino acid residue. The fluorine-containing peptide contained in the artificial virus capsid according to the present invention has a side chain that is -(Z 1 The amino acid residues other than (Rf)n4-(Rf)n3 are preferably amino acid residues of protein-constituting amino acids, D-isomers thereof, and modified amino acids in which the side chains of these amino acids have been modified.

[0068] Examples of protein-constituting amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan, asparagine, glutamine, proline, aspartic acid, glutamic acid, lysine, arginine, and histidine. Examples of modified protein-constituting amino acids include lysine, arginine, and histidine in which the hydrogen atom of the amino group in the side chain is substituted with one of the above-mentioned amino-protecting groups or a Pbf(N-ω-(2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl) group; aspartic acid and glutamic acid in which the hydrogen atom of the carboxy group in the side chain is substituted with one of the above-mentioned carboxy-protecting groups or a tert-butyl alkyl group; and cysteine ​​in which the hydrogen atom of the thiol group is substituted with a benzyl group.

[0069] The fluorine-containing peptide contained in the artificial virus capsid according to the present invention is preferably a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, in which the end linked to the divalent linking group is a cysteine ​​residue and the second residue from the end opposite the end linked to the divalent linking group is a fluorine-containing amino acid residue. The fluorine-containing peptide contained in the artificial virus capsid according to the present invention is particularly preferably a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, in which the N-terminus is a cysteine ​​residue and the second residue from the C-terminus is a fluorine-containing amino acid residue, in which a hydrogen atom in the side chain of a natural amino acid is substituted with -Rf or -Z.3 A peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, each of which is an amino acid residue substituted with -(Rf)n5, is preferred; a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, each of which is an amino acid residue substituted with -(Rf)n5, wherein the N-terminus is a cysteine ​​residue and the second C-terminus is a peptide consisting of a natural amino acid residue substituted with -Rf or -Z 3 A peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, in which the second amino acid residue from the N-terminus to the third amino acid residue from the C-terminus is independently an alanine residue or a glycine residue, is more preferred; a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, in which the N-terminus is a cysteine ​​residue and the second amino acid residue from the C-terminus is a cysteine ​​residue, in which a hydrogen atom in the side chain of a natural amino acid is substituted with -Rf or -Z 3 Further preferred is a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, in which the second amino acid residue from the N-terminus to the third amino acid residue from the C-terminus are independently an alanine residue or a glycine residue, and the C-terminus is a phenylalanine residue. 3 The amino acid residue substituted with -(Rf)n5 is an amino acid residue in which one or two hydrogen atoms of the amino group in the side chain of an arginine residue, an asparagine residue, a glutamine residue, or a lysine residue are substituted with -Rf or -Z 3 -(Rf)n5(Z 3 is a di-, tri-, or tetravalent linking group other than an alkylene group, provided that groups in which the linking moiety to Rf is an alkylene group are excluded. Also, n5 is 2, 3, or 4.) 3 an amino acid residue substituted with -(Rf)n5; an amino acid residue substituted with -Rf or -Z in which the hydrogen atom of the carboxyl group in the side chain of an aspartic acid residue or a glutamic acid residue is substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; a cysteine ​​residue or a methionine residue, wherein the hydrogen atom of the thiol group in the side chain is substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; a hydrogen atom of a hydroxy group in the side chain of a serine residue, a threonine residue, or a tryptophan residue substituted with -Rf or -Z 3an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the benzene ring in the side chain of a tyrosine residue or a phenylalanine residue are substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the imidazole ring in the side chain of a histidine residue substituted with -Rf or -Z 3 an amino acid residue substituted with -(Rf)n5; one to three hydrogen atoms of the indole ring in the side chain of a tryptophan residue are substituted with -Rf or -Z 3 It is preferably any of the amino acid residues substituted with -(Rf)n5.

[0070] In the artificial virus capsid according to the present invention, when the divalent linking group is linked to the N-terminus of the fluorine-containing peptide, the C-terminus of the fluorine-containing peptide may be protected with a protecting group. The protecting group at the C-terminus is not particularly limited as long as it is a protecting group for a carboxy group, and for example, a protecting group for a carboxy group used in peptide synthesis can be used. Specific examples of the protecting group for a carboxy group include a protecting group selected from the group represented by the following general formula (p-1), a 2-(9,10-dioxo)anthrylmethyl group, a benzyloxymethyl group, and a phenacyl group. In general formula (p-1), R 3 is an optionally substituted C 6-14 is an aryl group, and R 4 and R 5 are each independently a hydrogen atom or an optionally substituted C 6-14 It is an aryl group. The black circle represents a bond.

[0071]

[0072] Examples of the carboxy-protecting group include benzyl, diphenylmethyl, triphenylmethyl, 4-nitrobenzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 4-methylbenzyl, 2,6-dimethylbenzyl, 3-chlorobenzyl, 9-anthrylmethyl, piperonyl, 2-(9,10-dioxo)anthrylmethyl, benzyloxymethyl, phenacyl, etc. The protecting group for the C-terminal carboxy group is preferably a benzyl or triphenylmethyl group, more preferably a benzyl group, in that it can be deprotected under mild conditions.

[0073] In the artificial virus capsid according to the present invention, when the divalent linking group is linked to the N-terminus of the fluorine-containing peptide, the N-terminus of the fluorine-containing peptide may be protected with an amino-protecting group. The N-terminal protecting group is not particularly limited as long as it is an amino-protecting group, and for example, an amino-protecting group used in peptide synthesis can be used. Examples of amino-protecting groups include carbamate-based protecting groups such as a tert-butoxycarbonyl (Boc) group, a 9-fluorenylmethyloxycarbonyl (Fmoc) group, a benzyloxycarbonyl (Cbz) group, an allyloxycarbonyl (Alloc) group, and a 2,2,2-trichloroethoxycarbonyl (Troc) group. The tert-butoxycarbonyl (Boc) group or a 9-fluorenylmethyloxycarbonyl (Fmoc) group are preferred because they can be deprotected under mild conditions.

[0074] The fluorine-containing peptide contained in the artificial virus capsid according to the present invention is a raw material amino acid having at least one side chain of -(Z 1 The synthesis can be carried out by a general peptide synthesis method, except that an amino acid having a side chain of -(Z)n4-(Rf)n3 is used. For example, the synthesis can be carried out by a solid-phase peptide synthesis method. 1 )n4-(Rf)n3 as a starting material, can be easily synthesized using an automatic peptide synthesizer. 1 Amino acids with (Rf)n4-(Rf)n3 are preferred.

[0075] Peptides can be produced by sequentially condensing amino acids with protected amino groups with an amino acid whose C-terminus is bound to a solid phase, and then cleaving the peptide from the solid phase. It is preferable to use amino acid raw materials whose amino groups are protected with a Boc group or an Fmoc group. It is also preferable to use amino acid raw materials whose side chain functional groups are protected with a protecting group. Examples of protecting groups for side chain functional groups include a Boc group, a triphenylmethyl group, a benzyl group, and a 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) group.

[0076] Examples of condensing agents that form peptide bonds include N,N-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (WSC), benzotriazol-1-yloxy-trisdimethylaminophosphonium hexafluorophosphate (BOP), benzotriazol-1-yloxytrispyrrolizinophosphonium hexafluorophosphate (pyBOP), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, and 1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate (COMU). Furthermore, N-hydroxybenzotriazole (HOBt), ethyl (hydroxyimino)cyanoacetate (oxyma) and the above condensing agent can also be mixed in a preferred ratio and used.

[0077] Peptide bond formation may be achieved by activating the carboxy terminus, and examples of such activators include N-hydroxysuccinimide, p-nitrophenyl ester, and pentafluorophenyl ester. Examples of bases used in forming peptide bonds include triethylamine and diisopropylethylamine (DIPEA). Examples of solvents used in peptide bond formation reactions include chloroform, dichloromethane (DCM), dichloroethane (DCE), acetonitrile (MeCN), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and N-methyl-2-pyrrolidone (NMP).

[0078] The Boc and Fmoc groups, which are protecting groups for the amino-terminal amino group of a peptide or amino acid, can be removed with trifluoroacetic acid (TFA) or piperidine, respectively. Protecting groups for the side chain functional groups of amino acid residues of a peptide can be removed with, for example, TFA, hydrogen fluoride (HF), trifluoromethanesulfonic acid, etc.

[0079] In solid-phase peptide synthesis, a peptide having a protecting group attached to the side chain functional group of the peptide or amino acid residue can be removed from the solid-phase peptide synthesis resin using, for example, TFA. The removal of the peptide from the solid-phase peptide resin and the removal of the protecting group from the side chain functional group of the amino acid residue can be carried out simultaneously in the same reaction system. Alternatively, they can be carried out independently. Examples of commercially available resins that can be used for solid-phase peptide synthesis include 4-hydroxymethyl-3-methoxyphenoxybutyric acid-benzhydrylamine-polystyrene resin, p-benzyloxybenzyl alcohol-polystyrene resin, and oxime resin.

[0080] The target peptide or its intermediate can be isolated and purified by various methods, such as ion chromatography, gel filtration chromatography, reverse phase chromatography, normal phase chromatography, recrystallization, extraction, fractional crystallization, etc. Furthermore, the peptide thus obtained can be converted into its respective salt by a conventional method.

[0081] The protecting group of the amino group or carboxy group of the produced fluorine-containing peptide can be deprotected as necessary. The deprotection can be carried out by a conventional method depending on the type of protecting group.

[0082] <Divalent Linking Group> The divalent linking group that links the β-annulus peptide to the group derived from a fluorine-containing compound is not particularly limited as long as it is a divalent organic group. For example, Z 1 represents an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, a trivalent nitrogen atom, -C(=O)-, -S(=O) 2 -, a group in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, a group in which 2 to 4 hydrogen atoms have been removed from an aromatic ring (aryl group), a group in which 2 to 4 hydrogen atoms have been removed from a heterocycle (heteroaryl group), or a combination thereof. As the aryl group and heteroaryl group, the groups listed above can be used.

[0083] The divalent linking group possessed by the artificial virus capsid according to the present invention is preferably a divalent group having at least one group capable of selectively and easily bonding to a thiol group, since this group can easily bond to a cysteine ​​residue or the like. Examples of groups capable of selectively and easily bonding to a thiol group include a maleimide group, an iodoacetyl group, and a bromoacetyl group. Examples of the divalent linking group include bis-maleimide groups containing maleimide groups at both ends, such as the group represented by the following general formula (3):

[0084]

[0085] In general formula (3), the black circle represents a bond. One of the two black circles is bonded to the β-annulus peptide, and the other is bonded to a group derived from a fluorine-containing compound. By utilizing a chemical reaction that forms a thioether group from a maleimide group and a thiol group, it can be easily bonded to the thiol group of a cysteine ​​residue in the β-annulus peptide or to a thiol group in a group derived from a fluorine-containing compound. The reaction between a thiol group and a maleimide group can be carried out using a commonly used organic synthesis reaction.

[0086] In general formula (3), Z 4 represents an alkylene group, an oxygen atom (—O—), a sulfur atom (—S—), —NH—, —N(CH 3 ) -, -N(C 2 H 5 ) -, -N(C 3 H 7 )-, a trivalent nitrogen atom, -C(=O)-, -S(=O) 2 -, a group in which 2 to 4 hydrogen atoms have been removed from a cycloalkane, a group in which 2 to 4 hydrogen atoms have been removed from an aromatic ring (aryl group), a group in which 2 to 4 hydrogen atoms have been removed from a heterocycle (heteroaryl group), or a combination thereof. As the aryl group and heteroaryl group, the groups listed above can be used.

[0087] Z in general formula (3) 4 Specifically, Z 1 The same as those listed in the general formula (3) can be used. 4 Examples of the alkylene group include an alkylene group having 2 to 6 carbon atoms, -C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -C2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -Ph-, -Ph-CH 2 -Ph-, -C(=O)-, -C(=O)-O-, -OC(=O)-, -NH-C(=O)-O-, -OC(=O)-NH-, -C(=O)-NH-, -NH-C(=O)-, -S(=O) 2 -NH-, -NH-S (=O) 2 -, -S(=O) 2 —NH—S(═O) 2 -, -C(=O)-NH-Ph- are preferred, and an alkylene group having 2 to 6 carbon atoms, -C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 - or -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 It is more preferable that -Ph- is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group.

[0088] In the artificial viral capsid according to the present invention, the divalent linking group bonded to a group derived from a fluorine-containing compound can be bonded to the N-terminal side of the β-annulus peptide, but is preferably bonded to the C-terminal side of the β-annulus peptide. In an artificial viral capsid of a β-annulus peptide, which is essentially a hollow nanocapsule, the C-terminal side of the β-annulus peptide faces the outside of the nanocapsule. Therefore, by linking a group derived from a fluorine-containing compound to the C-terminal side of the β-annulus peptide, the group derived from the fluorine-containing compound can be presented on the surface of the artificial viral capsid, thereby more efficiently improving cell membrane permeability.

[0089] The artificial viral capsid according to the present invention may be linked to another substance at the end of the β-annulus peptide that is not linked to the divalent linking group. The other substance is not particularly limited as long as it does not inhibit the formation of the artificial viral capsid by self-assembly of the β-annulus peptide, and examples thereof include peptides, nucleic acids, low-molecular-weight compounds, and chimeric molecules consisting of two or more of these.

[0090] The artificial viral capsid according to the present invention has excellent cell membrane permeability due to the presence of groups derived from a fluorine-containing compound on its surface. Therefore, the artificial viral capsid is expected to be used in the pharmaceutical field as a physiologically active substance. For example, the artificial viral capsid according to the present invention is useful as a DDS carrier for transporting a target substance into cells. For example, in the artificial viral capsid according to the present invention, a target substance to be transported into cells is linked to the N-terminus of a β-annulus peptide, and the resulting artificial viral capsid is self-assembled to form the artificial viral capsid. The artificial viral capsid thus obtained encapsulates the target substance and, because its surface is modified with groups derived from a fluorine-containing compound, can efficiently take up the target substance into cells. Furthermore, in transfection, the cytotoxicity of the transfection reagent used also affects the efficiency of cellular introduction of the target substance. A highly cytotoxic reagent significantly reduces the survival rate of cells after introduction, resulting in low introduction efficiency. In contrast, the artificial viral capsid according to the present invention has relatively low cytotoxicity. Therefore, it is possible to efficiently incorporate the target substance into various cells without excessively reducing the cell viability.

[0091] The artificial viral capsid according to the present invention can also encapsulate a target substance to be delivered into a cell as a guest. For example, when subunits of the artificial viral capsid according to the present invention are self-assembled in an aqueous medium, the target substance can be dissolved or dispersed in the aqueous medium to obtain an artificial viral capsid encapsulating the target substance. The aqueous medium may be water, a buffer such as phosphate-buffered saline (PBS), or a solution of these containing a small amount of organic solvent.

[0092] The target substance to be encapsulated in the artificial viral capsid of the present invention and delivered into a cell is not particularly limited as long as it can be encapsulated in an artificial viral capsid formed from a β-annulus peptide. Examples include substances used for cell labeling, such as fluorescent substances and quantum dots, and physiologically active substances such as medicinal ingredients. The medicinal ingredient to be encapsulated in the artificial viral capsid of the present invention may be any of peptides, nucleic acids, low-molecular-weight compounds, and chimeric molecules consisting of two or more of these. Examples of nucleic acids include nucleic acids that contribute to RNA interference, such as siRNA, and nucleic acids for gene recombination and genome editing. In other words, the artificial viral capsid of the present invention can be used as an active ingredient in a DDS carrier composition by encapsulating a target substance therein.

[0093] In addition to the artificial viral capsid, the DDS carrier composition can be appropriately formulated with pharmaceutically acceptable carriers, excipients, additives, etc. An example of a suitable carrier is water, which may be an aqueous solution containing a salt (electrolyte) at a concentration suitable for administration to the human body, or a mixed solvent of water and an organic solvent such as alcohol. Routes of administration include, but are not limited to, oral, intravenous, intraarterial, intramuscular, subcutaneous, transdermal, intraperitoneal, intrathecal, rectal, vaginal, ocular, and inhalation.

[0094] By encapsulating a medicinal ingredient, the artificial virus capsid according to the present invention can be used to treat diseases for which the medicinal ingredient provides a therapeutic effect. That is, the artificial virus capsid according to the present invention can be used as an active ingredient in a pharmaceutical composition. A pharmaceutical composition can be prepared by encapsulating a therapeutically effective amount of a medicinal ingredient inside the artificial virus capsid in a DDS carrier composition. The subjects to which the artificial virus capsid according to the present invention or a composition containing the same is administered are typically individual animals, such as individual mammals, and particularly humans, but ex vivo tissues or cultured cells of these animals may also be administered.

[0095] The present invention will be described below with reference to examples, but the present invention is not limited to these examples.

[0096] The NMR apparatus used for the NMR analysis was a JNM-ECZ400S (400 MHz) manufactured by JEOL Ltd. 1 H NMR showed tetramethylsilane at 0 ppm, 19 F NMR shows C 6 F 6 was set as the reference value of -162 ppm.

[0097] [Measurement of particle size by dynamic light scattering (DLS)] The particle size of the artificial virus capsid in each sample was measured by dynamic light scattering. Measurements were performed at 25°C using a dynamic light scattering device DLS (Zetasizer Nano ZS, MALVERN) equipped with an incident He-Ne laser (633 nm) and a low-volume glass cuvette cell (ZEN2112, MALVERN). During the measurement, the sample diffusion intensity was displayed, and the correlation time of the scattering intensity G(τ) was measured 10 times, and the average value was applied to the following equation (1).

[0098] [B: baseline, A: amplitude, q: scattering vector, τ: delay time, D: diffusion coefficient:]

[0099] The hydrodynamic radius (R H ) was calculated using the Stokes-Einstein equation shown in the following formula (2).

[0100] [η: solvent viscosity, k B : Boltzmann's constant, T: absolute temperature.]

[0101] [Transmission Electron Microscopy (TEM)] Observation of the artificial viral capsids in each sample was performed using a TEM (JEM 1400 Plus, manufactured by JEOL). TEM grids (Thin Carbon Film TEM grids, manufactured by ALLANCE Biosystems) were hydrophilized using plasma treatment (25°C, 60 Hz, 500 VA, 40 s, JEOL HD Treatment). A sample solution (5 μL) was added to the hydrophilized TEM grid, allowed to stand for 1 minute, and then removed. Subsequently, a stain (5 μL, EM Stainer, manufactured by Nisshin EM) was added to the TEM grid, allowed to stand for 1 minute, and then removed. After staining, the grid was dried under reduced pressure and observed using a TEM at an accelerating voltage of 80 kV.

[0102] [Cell Culture] HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM). All media contained 10 v / v% fetal bovine serum (FBS), 100 μg / mL streptomycin, 100 units / mL penicillin, 1 mM sodium pyruvate, and 1 v / v% MEM nonessential amino acids. Cells were maintained in a 5% CO atmosphere. 2 The cells were maintained in an incubator at 37°C and subcultured every 3 to 4 days.

[0103] Example 1 An artificial virus capsid was formed by self-assembly of subunits in which a β-annulus peptide and a fluorine-containing peptide were linked via a Bis-maleimide group, and cell membrane permeability was examined.

[0104] (1) Synthesis of β-Annulus-Cys Peptide: The target amino acid sequence (H-Ile-Asn(Trt)-His(Trt)-Val-Gly-Gly-Thr(tBu)-Gly-Gly-Ala-Ile-Met-Ala-Pro-Val-Ala-Val-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Leu-Val-Cys(Trt)-Ser(tBu)-Alko-PEG resin; SEQ ID NO: 2) was elongated by Fmoc solid-phase synthesis using Fmoc-Ser-Alko-PEG resin (87 mg, 0.24 mmol / g; Watanabe Chemical Co., Ltd.). Deprotection (Fmoc removal) was performed by adding 2 mL of a piperidine / DMF solution (piperidine:DMF = 40:60 (volume ratio)) to a column containing the amino acid-incorporated resin. The column containing the resin was charged with an Fmoc group-containing amino acid / DMF solution, an HBTU / DMF solution, and HOBt.H 2Four equivalents of each of the 0H20 / DMF solution and the DIPEA / NMP solution were added, and the condensation reaction was carried out at room temperature for 2 hours. The resulting peptide-attached resin was deprotected (Fmoc removal) by adding a piperidine / DMF solution, washed with NMP, and then dried under reduced pressure. Next, a cleavage cocktail (a mixture of TFA / 1,2-ethanedithiol / triisopropylsilane / water / thioanisole = 2.58 / 0.09 / 0.03 / 0.15 / 0.15 (mL)) was added, and the mixture was treated at room temperature for 3 hours to cleave the peptide from the resin and deprotect the protecting groups on the amino acid side chains. The solution containing the recovered peptide was transferred to a centrifuge tube, and approximately 15 mL of methyl tert-butyl ether (MTBE) was added. The mixture was then centrifuged (3500 rpm, 10 minutes) to precipitate the peptide. This procedure was repeated three times, and the recovered precipitate was lyophilized to obtain the crude peptide as a white solid. The crude peptide was purified by reversed-phase HPLC using a C18 column (Inertsil WP300 C18 column; GL Science) with a linear gradient of MeCN / 0.1% TFA aqueous solution (5 / 95 to 100 / 0 over 100 minutes). The molecular weight of the target compound was identified by MALDI-TOF-MS (m / z = 2351, matrix: α-CHCA). Purified β-Annulus-Cys peptide (theoretical yield: 26.3 mg, yield: 18.1 mg, 69%) was obtained. Figure 1(A) shows the reversed-phase HPLC chart, and Figure 1(B) shows the MALDI-TOF-MS results.

[0105] (2) Synthesis of TMR-β-Annulus-Cys Peptide β-Annulus-Cys peptide labeled with the fluorescent dye tetramethylrhodamine (TMR) (TMR-β-Annulus-Cys peptide) was synthesized as follows: First, the target amino acid sequence (H-Ile-Asn(Trt)-His(Trt)-Val-Gly-Gly-Thr(tBu)-Gly-Gly-Ala-Ile-Met-Ala-Pro-Val-Ala-Val-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Leu-Val-Cys(Trt)-Ser(tBu)-Alko-PEG resin) was elongated by the same synthesis as in (1) above, followed by Fmoc removal. After Fmoc removal, 4 equivalents of TMR-COOH, 4 equivalents of COMU, 8 equivalents of DIPEA, and 2-3 mL of NMP were added to the resin and dissolved, followed by stirring for 3 hours in the dark. After the reaction, the solvent was removed and the mixture was washed five times with NMP and DCM. Cleavage of the peptide from the resin, deprotection of the amino acid side chain protecting groups, and recovery of the peptide powder were carried out in the same manner as in (1), yielding a crude peptide as a red powder. The crude peptide was purified by reverse-phase HPLC in the same manner as in (1), and the molecular weight of the target product was identified by MALDI-TOF-MS (m / z = 2763, matrix: α-CHCA). Purified TMR-β-Annulus-Cys peptide (theoretical yield: 5 mg, yield: 1 mg, yield: 20%) was obtained. FIG. 2(A) shows the reversed-phase HPLC chart, and FIG. 2(B) shows the results of MALDI-TOF-MS.

[0106] (3) Synthesis of β-Annulus-PEG2-maleimide β-Annulus-PEG2-maleimide was synthesized by conjugating bismaleimide-PEG2 (1,8-bismaleimido-diethyleneglycol) to the thiol group of the cysteine ​​residue two amino acid residues from the C-terminus of β-Annulus-Cys peptide. β-Annulus-PEG2-maleimide was synthesized as follows. First, acetonitrile (125 μL) was added to bismaleimide-PEG2 (1.5 mg) to dissolve it. Next, ion-exchanged water (375 μL) was added to β-Annulus-Cys peptide (1.2 mg) to dissolve it. The solution was then added to the bismaleimide-PEG2 / MeCN solution and reacted with shaking at 25°C for 24 hours (final concentrations: 1 mM β-Annulus-Cys peptide, 10 mM bismaleimide-PEG2). The reaction mixture was purified by reversed-phase HPLC in the same manner as in (1) above, and the molecular weight of the target product was identified by MALDI-TOF-MS (m / z = 2659, matrix: α-CHCA) to obtain purified β-Annulus-PEG2-maleimide (theoretical yield: 1.33 mg, yield: 0.60 mg, yield: 45.1%). Figure 3(A) shows the reversed-phase HPLC chart, and Figure 3(B) shows the MALDI-TOF-MS results.

[0107] (4) Synthesis of TMR-β-Annulus-PEG2-maleimide. TMR-β-Annulus-PEG2-maleimide was synthesized by conjugating Bismaleimide-PEG2 to the thiol group of the cysteine ​​residue two amino acid residues from the C-terminus of TMR-β-Annulus-Cys peptide. Bismaleimide-PEG2 (0.2 mg) was dissolved in DMSO (68 μL). TMR-β-Annulus-Cys peptide (0.6 mg) was dissolved in ion-exchanged water (612 μL). The solution was then added to the Bismaleimide-PEG2 / DMSO solution and allowed to react for 12 hours with shaking at 25°C (final concentrations: 333 μM TMR-β-Annulus-Cys peptide, 1 mM Bismaleimide-PEG2). The reaction mixture was purified by reversed-phase HPLC in the same manner as in (1) above, and the molecular weight of the target product was identified by MALDI-TOF-MS (m / z = 3071, matrix: α-CHCA) to obtain purified TMR-β-Annulus-PEG2-maleimide (theoretical yield: 166.5 nmol, yield: 14.24 nmol, yield: 8.6%). Figure 4(A) shows the reversed-phase HPLC chart, and Figure 4(B) shows the MALDI-TOF-MS results.

[0108] (5) CAD C8F17 Synthesis of F peptide CAD C8F17 F peptide (H-Cys-Ala-Asp(CF 17 )-Phe-NH2) was synthesized as follows: First, one hydrogen atom of the amino group in the side chain of aspartic acid was replaced with -Ph-CF 17 (a group in which one hydrogen atom of the phenyl group is substituted with a perfluoroalkyl group having 8 carbon atoms) 17 ) (D C8F17 ) was synthesized.

[0109]

[0110] 4-(perfluorooctyl)aniline (compound (1)) was synthesized according to the method described in Org. Lett., 2019, 21, 6481. In addition, in a dry 25 mL two-necked flask, 150 mg (0.3 mmol) of compound (1) and 130 mg (0.33 mmol, 1.1 equivalents) of Fmoc-Asp-OAll were dissolved in 6 mL of dichloromethane, and 141 mg (0.33 mmol, 1.1 equivalents) of COMU, 47 mg (0.33 mmol, 1.1 equivalents) of oxyma, and 85.3 mg (0.66 mmol, 2.2 equivalents) of DIPEA were added and stirred at room temperature for 16 hours. The reaction mixture was then quenched with HCl (1N) and extracted three times with dichloromethane. The combined organic phase was concentrated under reduced pressure, diluted with ethyl acetate, and washed with HCl (1N), saturated aqueous sodium bicarbonate, and saturated brine. The washed organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product of compound (2a). The crude product was dissolved in acetone and purified by reprecipitation using hexane to obtain a pure white solid of compound (2a) (Fmoc-Asp(C8F17)-OAll) (173 mg, 0.19 mmol). (Yield: 64.9%)

[0111] Compound (2a): 1 H NMR(400MHz,DMSO-D6) δ=7.87-7.77(m,5H),7.65-7.57(m,4H),7.37-7.22(m,4H),5.82(m,1H),5.26(d,J=17 .1Hz,1H),5.12(d,J=17.1Hz,1H),4.54(m,3H),4.29-4.18(m,3H),2.94-2.54(m,2H). 19 F NMR(376MHz,DMSO-D6) δ=-80.0(s,3F),-108.8(s,2F),-121.0(s,2F),-121.6(s,6F),-122.3(s,2F),-125.7(s,2F).

[0112]

[0113] To a solution of compound (2a) (173 mg, 0.2 mmol) in THF (2 mL), tris(dibenzylideneacetone)dipalladium(0) (10 mol%) and phosphine (20 mol%) were added at 0°C and stirred. Phenylsilane (2 equivalents) was then added, and the mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was then quenched with 1N HCl (10 mL) and extracted twice with dichloromethane. The organic phase was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (chloroform:methanol = 8:1 (volume ratio)) to obtain Fmoc-Asp(CF)-OH (compound (2b)) as a yellow solid (139 mg, 0.16 mmol, 82% yield).

[0114] Compound (2b): 1 H NMR(500MHz,DMSO-D6) δ=10.37(s,1H),7.85-7.21(m,12H),4.44(brs,1H),4.52-4.22(m,3H),2.90-2.68(m,2H). 19 F NMR(376MHz,DMSO-D6) δ=-80.06(s,3F),-108.83(s,2F),-122.36~-120.96(m,10F),-125.41(s,2F).

[0115]

[0116] The amino acids to be condensed were Fmoc-Phe-OH and Fmoc-Asp (CF 17 )-OH, Fmoc-Ala-OH, and Fmoc-Cys(Trt)-OH were used to synthesize CAD by Fmoc solid phase synthesis. C8F17 The F peptide (16 mg, 17 μmol, yield 22%) was obtained.

[0117] H-Cys-Ala-Asp(CF 17 )-Phe-NH2: LRMS(LC-MS)[M+H]+:m / z calcd for C 33 H 32 F 17 N6O5S + 947.69, found 947.54

[0118] (6) β-Annulus-CAD C8F17Synthesis of F peptide

[0119]

[0120] CAD C8F17 F peptide (7.1 mg) was dissolved in MeCN / 10 mM NaHCO 3 Aqueous solution (MeCN / 10mM NaHCO 3 β-Annulus-PEG2-maleimide powder (2.0 mg) was added to an aqueous peptide solution (750 μL) dissolved in β-Annulus-PEG2-maleimide (1 / 1 volume ratio) and the mixture was stirred at 25° C. for 24 hours to react (final concentrations: 1 mM β-Annulus-PEG2-maleimide, 10 mM CAD). C8F17 The reaction mixture was dialyzed against ion-exchanged water for 24 hours (Spectra / por7, cutoff Mw: 1000, manufactured by Spectrum), and then purified by reverse-phase HPLC using a C4 column (Inertsil WP300 C4 column; manufactured by GL Science) with a linear gradient of MeCN / 0.1% TFA aqueous solution (5 / 95 to 100 / 0 in 100 minutes). The molecular weight of the target substance was identified by MALDI-TOF-MS (m / z = 3604, matrix: α-CHCA), and the purified β-Annulus-CAD was identified. C8F17 The F peptide was obtained (theoretical yield: 2.7 mg, yield: 1.0 mg, yield: 37%). Figure 5(A) shows the reversed-phase HPLC chart, and Figure 5(B) shows the results of MALDI-TOF-MS.

[0121] (7) TMR-β-Annulus-CAD C8F17 Synthesis of F peptide CAD C8F17 F peptide (0.12 mg) was mixed with TMR-β-Annulus-PEG2-maleimide / DMSO solution (100 μL) and reacted with stirring at 25°C for 24 hours (final concentrations: 132 μM TMR-β-Annulus-PEG2-maleimide, 1320 μM CAD). C8F17The reaction mixture was purified by reversed-phase HPLC using a C4 column (Inertsil WP300 C4 column; GL Science) with a linear gradient of MeCN / 0.1% TFA aqueous solution (5 / 95 to 100 / 0 in 100 minutes). The molecular weight of the target substance was identified by MALDI-TOF-MS (m / z = 4017, matrix: α-CHCA). C8F17 The F peptide was obtained (theoretical yield: 13.2 nmol, yield: 2.1 nmol, yield: 15.6%). Figure 6(A) shows the reversed-phase HPLC chart, and Figure 6(B) shows the results of MALDI-TOF-MS.

[0122] (8) TMR-CAD C8F17 Synthesis of F peptide CAD C8F17 To the F peptide (0.0946 mg), 1.48 mM TMR-maleimide / DMSO solution (67.6 μL) and 200 mM phosphate buffer (pH 7.4, 932.4 μL) were added, and the mixture was stirred at 25° C. for 24 hours to react (final concentration: 100 μM CAD C8F17 F peptide, 100 μM TMR-maleimide). The reaction solution was purified by reversed-phase HPLC in the same manner as in (7) above, and the molecular weight of the target substance was identified by MALDI-TOF-MS (m / z = 1427, matrix: α-CHCA). C8F17 The F peptide was obtained (theoretical yield: 100 nmol, yield: 8.49 nmol, yield: 8.5%). Figure 7(A) shows the reversed-phase HPLC chart, and Figure 7(B) shows the results of MALDI-TOF-MS.

[0123] (9) Formation of fluorine-containing peptide-modified capsids: β-Annulus-CAD C8F17 The F peptide was self-assembled to form a fluorine-containing peptide-modified capsid. C8F17 F peptide (5 μL), DMSO solution (5 μL), and PBS (pH 7.4, 90 μL) were mixed and stirred for 30 seconds to form capsids (final concentration: 50 μM β-Annulus-CAD).C8F17 F peptide in 10% DMSO / PBS (pH 7.6). Also, 1 mM β-Annulus-CAD C8F17 F peptide (1 μL), DMSO solution (9 μL), and PBS (pH 7.4, 90 μL) were mixed and stirred for 30 seconds to form capsids (final concentration: 10 μM β-Annulus-CAD). C8F17 F peptide in 10% DMSO / PBS (pH 7.6).

[0124] The resulting capsids were measured by DLS to determine the particle size distribution (number function distribution). C8F17 The number-average particle size of the fluorine-containing peptide-modified capsids formed in a solution with an F peptide concentration of 50 μM was 97±26 nm (FIG. 8(A)). C8F17 The number-average particle size of the fluorine-containing peptide-modified capsids formed in a solution with an F peptide concentration of 10 μM was 81±76 nm (FIG. 8(B)). C8F17 A TEM image of fluorine-containing peptide-modified capsids formed in a solution with an F peptide concentration of 50 μM is shown in Figure 9. In the right image of Figure 9, isolated and dispersed fluorine-containing peptide-modified capsids are indicated by arrows.

[0125] (10) Formation of TMR-labeled fluorine-containing peptide-modified capsids TMR-β-Annulus-CAD C8F17 The F peptide was self-assembled to form a TMR-labeled fluorine-containing peptide-modified capsid. C8F17 F peptide (5 μL) and 1 mM TMR-β-Annulus-CAD C8F17 F peptide (0.5 μL), DMSO solution (5 μL), and PBS (pH 7.4, 90 μL) were mixed and stirred for 30 seconds to form capsids (final concentration: 50 μM β-Annulus-CAD). C8F17 F peptide and 5 μM TMR-β-Annulus-CAD C8F17 F peptide in 10% DMSO / PBS (pH 7.6).

[0126] The resulting capsids were measured by DLS to determine their particle size distribution (number function distribution). The number-average particle size of the formed TMR-labeled, fluorine-containing peptide-modified capsids was 209±61 nm ( FIG. 10 ).

[0127] (11) Intracellular introduction of fluorine-containing peptide-modified capsid (part 1) HepG2 cells were cultured in a single-well glass-bottom dish at a density of 2.0 × 10 4 100 μL of the solution was added to each well, and the mixture was incubated at 37°C in 5% CO 2 The mixture was left standing in an incubator for 24 hours. Then, TMR-labeled fluorine-containing peptide-modified capsid (50 μM β-Annulus-CAD) was added. C8F17 F peptide and 5 μM TMR-β-Annulus-CAD C8F17 F peptide), TMR-labeled fluorine-containing peptide (50 μM β-Annulus and 5 μM TMR-CAD C8F17 F peptide), or TMR-labeled capsid (50 μM CAD C8F17 F peptide and 5 μM TMR-CAD C8F17 100 μL of a solution of 10% FBS in DMEM (containing 10% FBS) was added, and the mixture was incubated at 37°C in 5% CO 2 The cells were incubated in an incubator for 3 hours. After incubation, the medium was removed and the cells were washed with PBS. 80 μL of the nuclear stain Hoechst 33342 (10 μg / mL) was added and incubated at 25°C for 10 minutes. After incubation, the nuclear stain solution was removed and the cells were washed with PBS. 100 μL of DMEM (containing 10% FBS) was added and the cells were observed under a confocal scanning microscope (CLSM, FLUOVIEW FV10i, Olympus). The TMR was detected using a filter used for rhod-2 detection (Ex: 553 nm, Em: 577 nm, sensitivity: 50%, laser intensity: 15%), and the Hoechst 33342 was detected using a blue fluorescence detection filter (Ex: 352 nm, Em: 455 nm, sensitivity: 50%, laser intensity: 15%). The fluorescence intensity of the capsid- or peptide-derived TMR introduced into HepG2 cells was determined using the image analysis software Image J by subtracting the fluorescence intensity outside the cells from the fluorescence intensity inside the cells (N=60).

[0128] Figure 11 shows TMR fluorescence images of each cell, merged images of the TMR fluorescence image and Hoechst 33342 fluorescence image, and transmitted light images taken with a confocal scanning microscope. In Figure 11, the upper row shows cells into which TMR-labeled, fluorine-containing peptide-modified capsids were introduced, the middle row shows cells into which TMR-labeled, fluorine-containing peptides were introduced, and the lower row shows cells into which TMR-labeled capsids were introduced. Figure 12 also shows the results of measuring the TMR fluorescence intensity of each cell. In Figure 12, the left column shows cells into which TMR-labeled, fluorine-containing peptide-modified capsids were introduced, the center column shows cells into which TMR-labeled, fluorine-containing peptides were introduced, and the right column shows cells into which TMR-labeled capsids were introduced.

[0129] As shown in Figure 11, red fluorescence of TMR was observed in the cells transfected with TMR-labeled fluoropeptide-modified capsids and cells transfected with TMR-labeled fluoropeptides, confirming that they were taken up into the cells. In particular, strong TMR fluorescence was observed in the cells transfected with TMR-labeled fluoropeptides, suggesting that the fluoropeptides (CADs) were the cytotoxic agents. C8F17 It was shown that the capsid itself (F peptide) has the ability to permeate the cell membrane. On the other hand, in cells transfected with TMR-labeled capsids, no TMR fluorescence was observed within the cells, indicating that capsids whose surfaces are not modified with fluorine-containing peptides are hardly taken up into the cells, and that modifying the surface with fluorine-containing peptides dramatically improves cell membrane permeability. Measurement of the TMR fluorescence intensity of individual cells by image analysis also confirmed that, although the amount of uptake was lower in cells transfected with TMR-labeled fluorine-containing peptide-modified capsids than in cells transfected with TMR-labeled capsids, there was a significant increase compared to cells transfected with TMR-labeled capsids.

[0130] (12) Intracellular introduction of fluorine-containing peptide-modified capsid (part 2) HepG2 cells were cultured at 3.0 × 10 5 500 μL of each was seeded into a 24-well plate so that cells / well were 2 The cells were cultured in an incubator for 48 hours. Then, TMR-labeled fluorine-containing peptide-modified capsid (50 μM β-Annulus-CAD) was added. C8F17F peptide and 5 μM TMR-β-Annulus-CAD C8F17 F peptide) solution, TMR-labeled fluorine-containing peptide (50 μM β-Annulus and 5 μM TMR-CAD C8F17 F peptide) solution, or TMR-labeled capsid (50 μM CAD C8F17 F peptide and 5 μM TMR-CAD C8F17 500 μL of F peptide solution was added, and the mixture was incubated at 37°C in 5% CO 2 The plates were left to stand in an incubator for 3 hours. After standing, the medium was removed, and the cells were detached from the plate by trypsinization and collected in a 1.5 mL plastic tube to obtain a cell suspension. The obtained cell suspension was centrifuged (800 g, 10 minutes, 4°C) to remove the supernatant. 500 μL of ice-cold FACS buffer (2% FBS-containing PBS(-)) was then added and suspended, followed by centrifugation under the same conditions and supernatant removal. This procedure was repeated twice. After removing the supernatant, 500 μL of FACS buffer was added and the cells were resuspended. Flow cytometry (detection wavelength: 577 nm, Gallios, Beckman) was performed three times on the obtained cell suspension. As a control, flow cytometry was performed in the same manner on untreated cells.

[0131] The TMR-labeled fluorine-containing peptide-modified capsid solution was prepared by adding 2.5 μL of β-Annulus-CAD C8F17 F peptide / DMSO stock solution (10 mM) and 0.25 μL of TMR-β-Annulus-CAD C8F17 The F peptide / DMSO stock solution (10 mM) and 122.25 μL of PBS (pH 7.4) were mixed in a 1.5 mL plastic tube, and the resulting solution was dialyzed for 12 hours (Dialysis tube, cutoff Mw: 1000 (1 kDa)) to remove DMSO. Then, 375 μL of DMEM (containing 10% FBS) was added to prepare a TMR-labeled, fluorine-containing peptide-modified capsid solution. The TMR-labeled, fluorine-containing peptide solution and the TMR-labeled capsid solution were also prepared by dialysis in the same manner.

[0132] The dot plots (left) and histograms (right) obtained by flow cytometry are shown in Figure 13. Figure 13(A) shows the results for untreated cells, Figure 13(B) shows the results for cells transfected with TMR-labeled fluorine-containing peptide-modified capsids, Figure 13(C) shows the results for cells transfected with TMR-labeled fluorine-containing peptides, and Figure 13(D) shows the results for cells transfected with TMR-labeled capsids. The histograms were calculated from the areas enclosed by ellipses in the dot plots. The percentage (%) of cells that incorporated TMR for each sample is shown in Figure 14(A), and the median TMR fluorescence intensity for each cell is shown in Figure 14(B).

[0133] As shown in Figure 13, first, normal cell populations were confirmed in the dot plots of all samples (the area surrounded by an ellipse in the dot plot on the left side of Figure 13). When a histogram of the fluorescence intensity of the normal cell population was created, higher intracellular fluorescence was detected in cells transfected with TMR-labeled fluorine-containing peptide-modified capsids and cells transfected with TMR-labeled fluorine-containing peptides compared to untreated cells and cells transfected with TMR-labeled capsids (Figure 13, right). As shown in Figure 14, it was confirmed that the TMR-labeled fluorine-containing peptide was taken up in approximately 90% of the cells transfected with TMR-labeled fluorine-containing peptide-modified capsids, and although the intracellular fluorescence intensity was lower than that of cells transfected with TMR-labeled fluorine-containing peptides, it was significantly higher than that of cells transfected with TMR-labeled capsids. These results also demonstrate that modifying the capsid surface with fluorine-containing peptides improves cell membrane permeability and increases intracellular introduction efficiency.

[0134] [Example 2] Drugs were encapsulated in fluorine-containing peptide-modified capsids, and the efficiency of their delivery into cells was examined. The β-Annulus-CAD synthesized in Example 1 was used as a subunit of the fluorine-containing peptide-modified capsid. C8F17 The F peptide was used. Doxorubicin (Dox) was used as the drug. For comparison, the β-Annulus-Cys peptide synthesized in Example 1 was used as a subunit for capsid formation that was not modified with a fluorine-containing peptide.

[0135] (1) Formation of Dox-encapsulated fluoropeptide-modified capsids 10 mM Dox / DMSO solution (1 μL) and 10 mM β-Annulus-CAD C8F17 After mixing with the F peptide / DMSO solution (1 μL), PBS (pH 7.4, 98 μL) was added and stirred for 30 seconds (final concentrations: 100 μM Dox, 100 μM β-Annulus-CAD). C8F17 F peptide). The resulting solution was dialyzed for 12 hours (Dialysis tube, cutoff Mw: 1000 (1 kDa)) to remove free Dox and DMSO, yielding Dox-encapsulated fluoropeptide-modified capsids. The Dox concentration after encapsulation (Dox binding rate (%)) was calculated by UV-vis spectrum measurement using the dialyzed solution with a Nanodrop ultra-microspectrophotometer (Thermo Scientific) (the molar extinction coefficient of Dox, ε 480 =11,500M -1 cm -1 ) (Non-Patent Document 5). Using the β-Annulus-Cys peptide, a capsid unmodified with a fluorine-containing peptide and encapsulating Dox was obtained in the same manner.

[0136] The resulting Dox-encapsulated fluoropeptide-modified capsids were analyzed by DLS to determine their particle size distribution (number function distribution), revealing a number-average particle size of 78±26 nm ( FIG. 15 ). A TEM image of the Dox-encapsulated fluoropeptide-modified capsid is shown in FIG. 16 . As shown in FIGS. 15 and 16 , even when Dox was encapsulated, the β-Annulus-CAD C8F17 The F peptide was shown to stably self-assemble to form capsids.

[0137] Furthermore, the UV-Vis spectra and Dox binding rates (%) of Dox-encapsulated fluoropeptide-modified capsids and Dox-encapsulated fluoropeptide-unmodified capsids are shown in Figure 17. The UV-Vis measurement results before and after dialysis were compared to calculate the Dox binding rate for each sample. The Dox binding rate for Dox-encapsulated fluoropeptide-modified capsids was 41%, while the Dox binding rate for Dox-encapsulated fluoropeptide-unmodified capsids was 14%. These results confirmed that fluoropeptide-modified capsids are useful as DDS carriers for encapsulating drugs such as Dox.

[0138] (2) Evaluation of cytotoxicity of Dox-encapsulated fluoropeptide-modified capsids The cytotoxicity of the Dox-encapsulated fluoropeptide-modified capsids prepared in (1) above and Dox-encapsulated fluoropeptide-unmodified capsids was examined by WST-assay to determine whether Dox taken up into cells by the fluoropeptide-modified capsids exerts its pharmacological effect.

[0139] First, the dialyzed capsid solution containing fluoropeptides encapsulated in Dox and the capsid solution containing fluoropeptides unmodified in Dox, prepared in (1), were each diluted 4-fold with DMEM(+) to prepare diluted capsid solutions. 4 100 μL of each was seeded into a 96-well plate so that each cell was counted per well. 2 The plates were cultured in an incubator at 37° C. for 24 hours. Then, the medium was removed, and the diluted capsid solution was added in an amount of 100 μL per well. 2 The cells were cultured in an incubator at 37°C for 24 hours. After the culture, the culture supernatant was removed, and a solution for measuring viable cell count (a mixed solution prepared by diluting 10 μL of Cell Counting Kit with 8 μL of medium) was added and cultured for 4 hours. The supernatant was then collected and diluted 10-fold, followed by UV-vis spectroscopy using a Nanodrop. The cell viability was calculated from the absorbance at an absorption wavelength of 460 nm (N=3). For comparison, a solution of Dox alone dissolved in DMEM(+), or a solution of Dox and the CAD synthesized in Example 1 was used. C8F17The cell viability was calculated in the same manner for cells cultured in a solution of F peptide dissolved in DMEM(+). The Dox concentration of each sample was standardized to 0.1 μM for comparison. The results of measuring cell viability (%) are shown in Figure 18.

[0140] The cytotoxicity evaluation showed that cells transfected with only Dox alone (control cells, "Dox" in the figure) and cells transfected with Dox and CAD C8F17 F peptide-introduced cells (in the figure, "2.4 μM CAD C8F17 In the cells transfected with capsids modified with fluoropeptides encapsulated in Dox (in the figure, "7.1 μM β-Annulus + Dox") and capsids modified with fluoropeptides encapsulated in Dox (in the figure, "7.1 μM β-Annulus + Dox"), the cell viability was 85% or higher, and almost no toxicity was observed. On the other hand, in the cells transfected with capsids modified with fluoropeptides encapsulated in Dox (in the figure, "2.4 μM β-Annulus-CAD"), the cell viability was 85% or higher, and almost no toxicity was observed. C8F17 In the case of "F+Dox", the cell viability was as low as 65%, indicating cytotoxicity (Figure 18). These results confirmed that even at a low Dox concentration of 0.1 µM, encapsulation of Dox into fluorine-containing peptide-modified capsids resulted in cytotoxicity due to Dox. These results demonstrate that fluorine-containing peptide-modified capsids are useful as anticancer drug transport carriers.

[0141] [Example 3] To investigate the intracellular uptake pathway of fluorine-containing peptide-modified capsids, the fluorine-containing peptide-modified capsids were uptaken into cells in the presence of an endocytosis inhibitor. As the fluorine-containing peptide-modified capsid, the TMR-labeled fluorine-containing peptide-modified capsid prepared in Example 1 (50 μM β-Annulus-CAD) was used. C8F17 F peptide and 5 μM TMR-β-Annulus-CAD C8F17 F peptide) was used.

[0142] First, HepG2 cells were plated in a single well of a glass-bottom dish at 2.0 × 10 4 100 μL of the solution was added to each well, and the mixture was incubated at 37°C in 5% CO 2After incubation in an incubator for 24 hours, 60 μL of DMEM (containing 10% FBS) containing 80 μM EIPA (5-(N-ethyl-N-isopropyl)-amiloride, a macropinocytosis inhibitor), 20 μM Pitstop 2 (N-[5-(4-bromobenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]naphthalene-1-sulfonamide, a clathrin-mediated endocytosis inhibitor), and 160 μM Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, a caveolae-mediated endocytosis inhibitor) was added to each well, and the cells were incubated at 37°C in 5% CO. 2 The cells were left to stand in an incubator for 30 minutes. Then, the medium was removed and the cells were washed with PBS(-). Then, each well was added with either 80 μM EIPA, 20 μM Pitstop 2, or 160 μM Genistein as an inhibitor, and TMR-labeled fluorine-containing peptide-modified capsid (50 μM β-Annulus-CAD C8F17 F peptide and 5 μM TMR-β-Annulus-CAD C8F17 60 μL of DMSO-containing DMEM (containing 10% FBS and 5% DMSO) containing 10% FBS and 10% F peptide was added to each well, and the mixture was incubated at 37°C in 5% CO 2 As a control, the cells were incubated in a DMSO-containing DMEM (containing 10% FBS and 5% DMSO) containing only the TMR-labeled fluorine-containing peptide-modified capsid at 37°C in 5% CO 2 The cells were allowed to stand for 3 hours in an incubator. After standing, the medium was removed and the cells were washed with PBS. 80 μL of the nuclear stain Hoechst 33342 (10 μg / mL) was added and the cells were allowed to stand for 10 minutes at 25°C. After standing, the cells were washed with PBS in the same manner as in Example 1 and stained with the nuclear stain Hoechst 33342. Then, the cells were observed with a confocal scanning microscope to determine the fluorescence intensity of the TMR derived from the capsid introduced into the HepG2 cells.

[0143] Figure 19 shows TMR fluorescence images of each cell captured with a confocal scanning microscope. Figure 20 also shows the results of measuring the intracellular TMR fluorescence intensity of each cell. The P value of the TMR fluorescence intensity was calculated using the Kruskal-Wallis test (Dunn test). As shown in Figures 19 and 20, it was confirmed that intracellular red fluorescence was significantly reduced in cells cultured in a medium containing Genistein, an inhibitor of caveolae-dependent endocytosis, and TMR-labeled, fluorinated peptide-modified capsids. These results suggest that fluorinated peptide-modified capsids are primarily taken up into cells via caveolae-dependent endocytosis.

[0144] Example 4 β-Annulus-CAD C6F13 F peptide self-assembles to form CAD C6F13 We prepared F peptide-modified artificial viral capsids and examined their cell membrane permeability.

[0145] (1) β-Annulus-CAD C6F13 Synthesis of F peptide

[0146]

[0147] 10 mM β-Annulus-PEG2-maleimide in DMF (2.5 μL), 10 mM CAD C6F13 A DMF solution of F peptide (2.5 μL) and 35 μL of DMF were mixed and stirred at 25°C for 24 hours. The reaction mixture was stirred for 24 hours. The DMF was removed using a concentrator (Convenience Evaporator; BioChromato). The resulting solution was dissolved in 50 μL of trifluoroethanol and purified by reversed-phase HPLC using a C4 column (Inertsil WP300 C4 column; GL Science) with a linear gradient of MeCN / 0.1% TFA solution (5 / 95 to 100 / 0 over 100 minutes). The molecular weight of the target compound was identified by ESI-MS (m / z = 877.1357, Calcd. [M+4H]). 4+ = 877.1362), purified β-Annulus-CAD C6F13The F peptide was obtained (theoretical yield: 1.75 mg, yield: 0.2 mg, yield: 27%). Figure 21(A) shows the reversed-phase HPLC chart, and Figure 21(B) shows the ESI-MS results.

[0148] (2) Preparation of mRNA-encapsulating artificial virus capsids and their intracellular introduction

[0149]

[0150] dT 20 The -SS-β-Annulus peptide conjugate was prepared as described in the literature (Applied Sciences, 2020, 10, 8004). 500 μM β-Annulus-CAD was added to an Eppendorf tube. C6F13 F peptide aqueous solution 1 μL, 500 μM Unmodified β-Annulus peptide aqueous solution 1.28 μL, 10 μM dT 20 11 μL of β-SS-Annulus aqueous solution was added and freeze-dried. 20 μL of 1.1 μM mCherry mRNA (OZBIOSCIENCES) dissolved in nuclease-free water was added to the peptide powder and slowly pipetted. After that, the mixture was incubated at 37°C for 30 minutes in a constant temperature bath to obtain CAD data. C6F13 We constructed an artificial viral capsid encapsulating F peptide-modified mRNA.

[0151] HepG2 cell-immobilized dish (cell density: 4.0 x 10 4 50 μL of each prepared sample was inoculated onto a 100 μL plate (100 cells / 100 μL) and incubated at 37°C in 5% CO 2 After the solvent was removed and the cells were washed with PBS, 80 μL of 1 μg / mL Hoechst 33342 in DMEM medium (containing 10% FBS) was added, and the cells were incubated at 37°C in 5% CO 2The cells were incubated for 10 minutes. After removing the solvent and washing with PBS, 100 μL of DMEM medium (containing 10% FBS) was added, followed by observation under a confocal scanning microscope (CLSM, FLUOVIEW FV10i, Olympus). mCherry expressed in HepG2 cells was detected using Ex: 584 nm, Em: 610 nm, sensitivity: 50%, laser intensity: 15%. Hoechst 33342 was detected using Ex: 352 nm, Em: 455 nm, sensitivity: 50%, laser intensity: 15%. The fluorescence intensity of mCherry expressed in HepG2 cells was measured using the image analysis software Image J, and the value obtained by subtracting the fluorescence intensity outside the cells from the fluorescence intensity inside the cells was used (N = 60).

[0152] Hoechst 33342 fluorescent images, mCherry fluorescent images, merged images of the mCherry and Hoechst 33342 fluorescent images, and transmitted light images of each cell captured with a confocal scanning microscope are shown in Figure 22. Furthermore, the results of measuring the mCherry fluorescent intensity of each cell are shown in Figure 23. In Figure 23, the left column shows cells into which mCherry mRNA was introduced using a transfection reagent (Lipofectamine MessengerMAX), and the center column shows cells into which CAD mRNA was introduced. C6F13 The right column shows cells into which mCherry mRNA was introduced using an F peptide-modified artificial viral capsid, and the left column shows cells into which mCherry mRNA was introduced using an unmodified artificial viral capsid.

[0153] As shown in Figure 22, transfection reagent and CAD C6F13 In cells into which mCherry mRNA was introduced using the F peptide-modified artificial viral capsid, red fluorescence of mCherry was observed within the cells, confirming that the mRNA had been taken up into the cells and that mCherry had been expressed. C6F13The fluorescence intensity when mCherry mRNA was introduced using the F peptide-modified artificial viral capsid was slightly lower than when a transfection reagent was used, but was almost the same. Furthermore, the fluorescence intensity was about five times higher than when mCherry mRNA was introduced using an unmodified artificial viral capsid. These results suggest that CAD C6F13 By modifying F into an artificial viral capsid, it was confirmed that mRNA was sufficiently delivered and expressed in cells.

Claims

1. An artificial viral capsid formed by the self-assembly of a plurality of subunits, wherein the subunits contain a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound, and a divalent linking group that links the β-annulus peptide to the group derived from the fluorine-containing compound, and the divalent linking group is linked to the C-terminus of the β-annulus peptide.

2. The artificial virus capsid described in claim 1, wherein the fluorine-containing compound is a fluorine-containing peptide.

3. At least one side chain of the amino acid residue constituting the fluorine-containing peptide is represented by the following general formula (1): [In the formula, Z 1 is a di-, tri-, or tetravalent linking group other than an alkylene group; Rf is a C 1-30 Alkyl group (the C 1-30 When the alkyl group has two or more carbon atoms, it may have 1 to 5 ether-type oxygen atoms between the carbon atoms), -SF 5 , or -SF 4 -CR 101 R 102 -CR 103 R 104 Cl(R 101 , R 102 , R 103 , and R 104 are each independently a hydrogen atom, a fluorine atom, or a chlorine atom, and R 101 , R 102 , R 103 , and R 104 wherein two or more of n1, n2, n3, n4, n5, n6, n7, n8, n9, n10, n11, n12, n13, n14, n15, n16, n17, n18, n19, n20, n21, n22, n33, n44, n45, n46, n47, n48, n49, n50, n51, n52, n53, n54, n55, n56, n57, n58, n59, n60, n61, n62, n63, n64, n65, n66, n67, n68, n69, n70, n71, n72, n73, n74, n75, n76, n76, n81, n97, n98, n99, n100, n101, n102, n103, n104, n105, 4. The Rf is represented by the following general formula (f-1) or (f-2): [wherein, Rf P is a fully halogenated C containing at least two or more fluorine atoms. 1-10 Alkyl group (the fully halogenated C 1-10 The artificial virus capsid according to claim 3, wherein the alkyl group is a group represented by the following formula: when the alkyl group has two or more carbon atoms, it may have an ether-bonding oxygen atom between the carbon atoms, n1 is an integer of 0 to 10, n2 is an integer of 0 to 9, and a black circle represents a bond.

5. The artificial virus capsid according to claim 3, wherein the amino acid residue having a group represented by general formula (1) in a side chain is an amino acid residue having 1 to 3 of the Rf's linked directly or indirectly to the side chain of a natural amino acid.

6. The artificial virus capsid according to claim 1, wherein the divalent linking group is a Bis-maleimide group containing maleimide groups at both ends.

7. The artificial virus capsid described in claim 1, wherein the β-annulus peptide has a cysteine ​​residue at or near the C-terminus, and the divalent linking group is linked to a thiol group derived from the cysteine ​​residue.

8. A pharmaceutical composition comprising the artificial virus capsid according to any one of claims 1 to 7.

9. A drug delivery carrier composition comprising the artificial virus capsid according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Sheet ejection device, sheet processing device and image forming system

    JP2023076053A

  • Perfluorinated compounds for the non-viral transfer of nucleic acids

    WO2012130941A2

  • Perfluoro alkyl group-containing nucleic acid and production method therefor

    WO2021060506A1

  • Artificial virus capsid

    JP2022173834A

  • Vaccines based on an antigen protein fused to a nanostructuring scaffold

    WO2022043449A1